Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Stoke Therapeutics, Inc.NASDAQ: STOK
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 43.4% from a year ago
Cash & equivalents stood at $155.66M at the end of Q1 FY2026, down 43.4% from a year earlier and up 84.8% from the prior quarter. Over 3 fiscal years it compounded at -9.5% a year.
Context
- Cash & equivalents amounted to 35.1% of total assets at the end of Q1 FY2026, down 32.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -43.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 84.22M USD
- Year-over-year change
- -34.2%
- 4-year CAGR
- -12.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 84.22M | -34.2% |
| FY2024 | 2024-12-31 | 127.98M | -33.1% |
| FY2023 | 2023-12-31 | 191.44M | +68.6% |
| FY2022 | 2022-12-31 | 113.56M | -21.6% |
| FY2021 | 2021-12-31 | 144.9M | — |
Cash & Equivalents vs competitors
How STOK compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -43.4% is the 6th highest of 7, against a peer median of -17.3%.
- Cash & equivalents amounts to 35.1% of total assets for STOK, versus a peer median of 13.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $544.59M USD | +124.0% | +89.5% | 93.3% | |
| Sep 2026 | $296.3M USD | -12.4% | +10.4% | 10.2% | |
| Jun 2026 | $219.83M USD | -22.1% | +8.2% | 15.9% | |
| Mar 2026 | $155.66M USD | -43.4% | -9.5% | 35.1% | |
| Mar 2026 | €81.17M EUR | -43.2% | -0.9% | 81.9% | |
| Mar 2026 | $12.77M USD | -6.6% | -14.0% | 5.5% | |
| Mar 2026 | $5.66M USD | -91.3% | -41.0% | 4.9% | |
| Peer median (excluding STOK) | — | -17.3% | +3.7% | 13.0% | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 144.9M | 113.56M | 191.44M | 127.98M | 84.22M |
| Short-term Investments | 74.92M | 116.04M | 9.95M | 88.92M | 200.45M |
| Net Receivables | 132K | 588K | 64K | 700K | 7.91M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.33M | 2.96M | 2.56M | 4.04M | 4.39M |
| Total Current Assets | 229.22M | 244.07M | 215.34M | 232.76M | 305.7M |
| Property, Plant & Equipment (Net) | 9.08M | 11.43M | 12.43M | 8.25M | 6.25M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 29.82M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 569K | 569K | 569K | 721K | 106.49M |
| Total Non-current Assets | 9.65M | 12M | 13M | 38.8M | 112.73M |
| Total Assets | 238.87M | 256.07M | 228.34M | 271.56M | 418.43M |
| Account Payables | 2.39M | 766K | 1.7M | 2.5M | 4.94M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 14.88M | 15.31M | 18.99M | 11.9M |
| Other Current Liabilities | 5.92M | 6.26M | 6.47M | 8.44M | 15.04M |
| Total Current Liabilities | 17.14M | 31.39M | 30.82M | 40.06M | 57.88M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 36.86M | 33.07M | 0 | 6.96M |
| Other Non-current Liabilities | 3.95M | 2.97M | 4.88M | 2.48M | 1.14M |
| Total Non-current Liabilities | 3.95M | 39.82M | 37.96M | 2.48M | 8.1M |
| Total Liabilities | 21.09M | 71.22M | 68.78M | 42.53M | 65.98M |
| Common Stock | 4K | 4K | 5K | 5K | 5K |
| Retained Earnings | (196.08M) | (297.15M) | (401.85M) | (490.83M) | (497.72M) |
| Accumulated OCI | (168K) | (1.18M) | (24K) | (151K) | 543K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 217.78M | 184.85M | 159.57M | 229.02M | 352.46M |
| Total Debt | 1.51M | 2.36M | 2.06M | 2.32M | 3.01M |
| Net Debt | (143.39M) | (111.2M) | (189.38M) | (125.66M) | (81.21M) |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.